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Abstract 30 
Objective 31 
To determine if HPV immunisation has affected the prevalence of HPV genotypes and 32 
colposcopic features of CIN in young women referred for colposcopy. 33 
 34 
Design 35 
A two-centre observational study including vaccinated and unvaccinated women. 36 
 37 
Setting 38 
Colposcopy clinics serving two health regions in Scotland, UK. 39 
 40 
Population 41 
361 women aged 20-25 years attending colposcopy following an abnormal cervical 42 
cytology result at routine cervical screening.  43 
 44 
Methods 45 
Cervical samples were obtained from women for HPV DNA genotyping and mRNA 46 
E6/E7 expression of HPV 16,18,31,33 and 45. Demographic data, cytology and 47 
histology results and colposcopic features were recorded. Chi squared analysis was 48 
conducted to identify associations between vaccine status, HPV genotypes and 49 
colposcopic features. 50 
 51 
Main outcome measures 52 
Colposcopic features, HPV genotypes, mRNA expression and cervical histology.  53 
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 54 
Results 55 
The prevalence of HPV 16 was significantly lower in the vaccinated (8.6%) compared 56 
with the unvaccinated (46.7%) group (p=0.001). The number of cases of cervical 57 
intraepithelial neoplasia 2 or more (CIN2+) was significantly lower in vaccinated 58 
women (p=0.006).HPV vaccine did not have a statistically significant  effect on 59 
commonly recognised colposcopic features but there was a slight reduction in the 60 
positive predictive value (PPV) of colposcopy for CIN2+ from 74% (unvaccinated) to 61 
66.7% (vaccinated). 62 
 63 
Conclusions 64 
In this group of young women with abnormal cytology referred to colposcopy, HPV 65 
vaccination via a catch-up programme reduced the prevalence of CIN2+ and HPV 16 66 
infection. The reduced PPV of colposcopy for the detection of CIN2+ in vaccinated 67 
women is at the lower acceptable level of the UK national cervical screening 68 
programme guidelines. 69 
Word count 246 70 
 71 
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Tweetable Abstract 75 
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Introduction  79 
HPV immunisation has been a major advance in the prevention of cervical disease 80 
and cancer. In September 2008, the bivalent vaccine (which protects against HPV 16 81 
and 18) was introduced in the UK as part of the school-based immunisation 82 
programme.1 The vaccine is given to girls aged 12-13 years and current uptake rate 83 
in schools in Scotland is 90%.2 When the vaccine was introduced, it was also offered 84 
to girls aged 14-17 as part of a catch up campaign: 65.5% of the eligible catch up 85 
group in Scotland received the full three doses.2Within the school vaccination 86 
programme the bivalent vaccine was used initially (2008-2010) but since 2011 it was 87 
changed to the quadrivalent vaccine.  88 
 89 
While prophylactic HPV vaccines offer primary protection against the highest risk HPV 90 
types, as well as a level of cross protection for other high risk HPV types (HPV 91 
31,33,45)3.  However, there will still be a residual risk of disease conferred by other 92 
high risk HPV genotypes which are not covered by the currently licensed vaccine(s). 93 
Therefore, there is a continued need for secondary prevention using cervical screening 94 
and colposcopy.  95 
 96 
In Scotland cervical screening, using liquid based cytology, is offered to all women 97 
aged 20-60 years with referral to colposcopy for further investigation if the cytology 98 
shows high grade dyskaryosis or repeated low grade dyskaryosis or borderline nuclear 99 
abnormalities (BNA).4,5 HPV triage is not part of the screening programme in Scotland. 100 
 101 
There is inconsistent evidence as to whether the appearance of the cervix during 102 
colposcopy is influenced by the HPV genotypes present.6-9 A study by Jeronimo et al. 103 
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found that colposcopic features characteristic of high grade cervical intraepithelial 104 
neoplasia (CIN) imply infection with HPV 16 but not necessarily other HPV types.6 It 105 
has also been shown that lesions missed during colposcopy are more likely to be HPV 106 
16 negative than HPV 16 positive.7,8 In contrast, van der Marel et al. showed that the 107 
visual appearance of high grade HPV16 lesions at colposcopy is not different from 108 
lesions associated with other high risk HPV genotypes.9However, these studies do not 109 
include women who had been vaccinated against HPV infection. If the appearance of 110 
the cervix is associated with HPV genotypes present, it would be anticipated that HPV 111 
vaccination might alter the range of features seen at colposcopy and thereby 112 
potentially affect the performance of colposcopy.   113 
 114 
In this study, we investigated cervical abnormalities, HPV genotypes and performance 115 
of conventional colposcopic evaluation in both vaccinated and unvaccinated women 116 
aged 20-25 years attending colposcopy. 117 
 118 
Methods 119 
Study design and population: This two centre cross-sectional study was conducted 120 
with women aged 20-25 years routinely attending colposcopy clinics following an 121 
abnormal cervical cytology result in two Scottish teaching hospitals (Aberdeen Royal 122 
Infirmary and Edinburgh Royal Infirmary) serving regional populations. The first group 123 
(Group 1) of women was recruited between February 2010 and March 2011(before 124 
women vaccinated as part of the catch-up immunisation campaign had entered the 125 
cervical screening programme) and the second group (Group 2) of women was 126 
recruited from December 2012 to November 2014 (after women vaccinated as part of 127 
the catch up campaign had entered the screening programme).Some individuals 128 
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(2008-2010) will have received Gardasil, through private arrangement, out with the 129 
catch up programme. 130 
 131 
 132 
Recruitment& Consent: Women were eligible if they attended colposcopy for the first 133 
time following an abnormal cytology result at routine cervical screening. Women were 134 
excluded if they were unable to understand the patient information leaflet (PIL), if they 135 
were pregnant at the time of colposcopy or if they were being referred as a 136 
consequence of symptoms.  Eligible women were sent an invitation letter and 137 
information before attending for colposcopy.  At their appointment, written consent was 138 
obtained if they wished to take part in the study. 139 
 140 
Data collection: Participants were assigned a unique study number and data were 141 
collected on age, referral cytology, parity and vaccination status (including vaccine 142 
type, number of doses and age at last dose). Women were considered to be 143 
vaccinated if they received two or more doses of a HPV vaccine.10Information on 144 
vaccine status was obtained from the Scottish Cervical Call-Recall System (SCCRS). 145 
SCCRS is the national cervical screening database that contains cytology results, 146 
associated histopathology, recall and management data and also immunisation status. 147 
 148 
Colposcopy:Colposcopy was performed by BSCCP-accredited colposcopists, who 149 
recorded their findings using standard reporting features.Colposcopists were blind to 150 
the HPV status of the patient. Samples for HPV genotyping were obtained using a 151 
broom sampler before the application of acetic acid and were stored in ThinPrep® 152 
PreservCyt®(©Hologic UK, Crawley, West Sussex, UK).Biopsies were taken if 153 
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features indicative of CIN were seen at colposcopy, including acetowhite changesand 154 
capillary vessel patterns $ µVHe DQG WUHDW¶ DSSURDFK ZDV FRQVLGHUHG IRU ZRPHQ155 
referred with high grade dyskaryosis, as per local protocols.  If a punch biopsy or 156 
diathermy loop excision treatment was undertaken, these had a histological diagnosis 157 
within the local NHS pathology laboratory.  Histology results were captured from 158 
pathology records. 159 
 160 
HPV genotyping: Samples were tested at the Scottish HPV Reference Laboratory, 161 
Edinburgh for the presence of 37 HPV genotypes using QIAamp® Media 162 
MDx11followed by LINEAR ARRAY HPV Genotyping Test (Roche Molecular 163 
Systems).12High-risk HPV types were considered to be: 16, 18, 31, 33, 35, 39, 45, 51, 164 
52, 56, 58, 59 and 68. Intermediate risk HPV types were: 26, 53, 64, 66, 67, 69, 70, 165 
73, 82, IS39 and CP6108. All other HPV genotypes that were identified were 166 
considered to be low-risk.13 167 
 168 
A sub-set of samples (N=319;88%), based on availability of samples, were also tested 169 
for mRNA expression using PreTect HPV-Proofer (Norchip AS, Klokkarstua, Norway) 170 
which detects E6/E7 mRNA from HPV 16, 18, 31, 33 and 45.14 171 
 172 
 173 
Statistical analysis: All statistical analyses were performed using SPSS Version 20 174 
(IBM SPSS Statistics for Windows, Version 20.0, Armonk, NY: IBM Corp.) Chi-squared 175 
analysis was used to test for associations between vaccine status and colposcopic 176 
features, colposcopic opinion, histology results and HPV genotypes. All p values were 177 
two sided and for the chi-squared analysis were considered significant if their value 178 
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was less than 0.05.  Z-tests of two proportions were used to assess the difference in 179 
prevalence for each of the 35 types genotyped. As multiple statistical tests were 180 
conducted, the significance threshold for the z-tests was subject to the Bonferroni 181 
correction and therefore considered significant if their value was less than 0.00143 182 
(=0.05/35). 183 
 184 
Performance analysis of colposcopy was conducted using histology results as the gold 185 
standard for final diagnosis.  In cases where no biopsy was indicated, women were 186 
assumed to have no significant disease.  Sensitivity, specificity, PPV and NPV of 187 
colposcopy were calculated for detection of high grade disease (CIN2+); a positive 188 
WHVWZDVFRQVLGHUHGWREHDFROSRVFRSLFRSLQLRQRI³KLJKJUDGH´Comparisons were 189 
made between vaccinated and unvaccinated women, and also between those who 190 
were positive and those who were negative for DNA HPV16.  Differences in the 191 
performance of colposcopy between groups were assessed using z-tests. 192 
 193 
Statistical power: Power analysis was conducted to calculate how many participants 194 
were necessary to reach adequate sample size using EPISTAT software.  The 195 
proportion of high risk types was estimated from previously published research.13 A 196 
1:1 ratio for HPV 16/18 against all other HPV types was used. It was estimated 400 197 
women would give 95% power to detect a reduction in PPV of colposcopy from 70% 198 
to 52.5% between 200 HPV16/18 positive women and 200 women who did not have 199 
HPV16/18.  If only 200 women in total were recruited (100 with and 100 without 200 
HPV16/18) there would be an 86% power to detect a 30% reduction from 70% to 40%. 201 
 202 
Results 203 
9 
 
Recruitment 204 
Figure S1: Flow diagram of recruitment and study processes 205 
A flow diagram of recruitment and study processes is included in supplementary 206 
information. In Group 1 (recruited before women eligible for the HPV vaccine in the 207 
catch up campaign entered the cervical screening programme) 208 women agreed to 208 
participate,10 were excluded because they did not have a sample taken for HPV 209 
testing.  Of the 198 women included in the final analysis, 172 had both HPV mRNA 210 
and DNA tests. In Group 2 (recruited after women eligible for the HPV vaccine in the 211 
catch up campaign entered the cervical screening programme) 175 women agreed to 212 
take part, 12 were excluded because they did not have a sample for HPV testing or 213 
colposcopy data.  Of the 163 included in analysis, 147 had both HPV mRNA and DNA 214 
tests. 215 
 216 
Participant Demographics 217 
Table S1shows the participant characteristics for each group. Vaccine status was self-218 
reported in Group 1 (three women (2%) reported being vaccinated: two received the 219 
quadrivalent vaccine and one received the bivalent vaccine).As this could not be 220 
verified by SCCRS at the time, all women were considered unvaccinated. In Group 2 221 
the vaccine status was verified by SCCRS and 67 (41%) women were vaccinated. The 222 
mean age at colposcopy in both groups was 22 years.  For those vaccinated, the mean 223 
age at last dose was 17.3years (SD1.2).  224 
Table 1: Participant Demographic data by group 225 
 226 
Impact of vaccination on colposcopic features and histology 227 
Table 2: Impact of vaccination status on colposcopic features and histology 228 
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As shown in Table 2, the proportions of women with acetowhite changes (79% vs 229 
77%), mosaic (44% vs 43%), punctation (38% vs 39%)or atypical vessels(1% vs 1%) 230 
were similar in both unvaccinated and vaccinated groups respectively. There was no 231 
significant impact on non-iodine staining epithelium, which is noted in a higher 232 
proportion of vaccinated women (56%) compared to unvaccinated women (50%; 233 
p=0.44). However, the use of iodine was inconsistent between colposcopists, and was 234 
not applied in 100 cases limiting any conclusions. Colposcopists were significantly 235 
more likely to record their opinion as high grade in unvaccinated women (34%) 236 
compared to vaccinated women (20%; p=0.027), a difference of 14% (95% CI 2%, 237 
26%).  Unvaccinated women were also more likely to have high grade disease (CIN2+) 238 
36%, compared to 19% in vaccinated women, p=0.006; a difference of 17% (95% CI 239 
5%, 29%).  Unvaccinated women were also more likely to have any grade of CIN 240 
(CIN1+); 63% compared to 46% in vaccinated p=0.044, a difference of 17% (95% CI 241 
2%, 30%). 242 
 243 
All eight cases of invasive squamous carcinoma or CGIN were identified in 244 
unvaccinated women. All three cases of CIN3 identified in vaccinated womenwere 245 
HPV 16 and 18 negative on cervical samples; two of these were associated with HPV 246 
33 (mRNA and DNA positive) and one with HPV 52(DNA positive). A higher proportion 247 
of vaccinated women (40% compared with 28% unvaccinated) did not have a biopsy 248 
taken (i.e. the colposcopic appearance did not indicate any significant disease).  249 
 250 
HPV Genotyping Results 251 
Figure 1: HPV genotyping results 252 
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Figure 1 demonstrates the HPV genotypes that were present in vaccinated and 253 
unvaccinated women. Only six vaccinated women (9%) had HPV 16, a significantly 254 
lower proportion than the unvaccinated group (47%; p<0.001). Two (3%) of the 255 
vaccinated women had an HPV 18 infection, compared to 17% of the unvaccinated 256 
women (p=0.003). High risk HPV types 52, 56 and 58 were found to be present in a 257 
higher proportion of women in the vaccinated group than in the unvaccinated 258 
group(23% vs 13%;p = 0.039, 16% vs 6%;p=0.023 and 13% vs 6%;p=0.029 259 
respectively).The changes in HPV 18, 52, 56 and 58 are not considered statistically 260 
significant when multiple statistical testing is accounted for.  For all other high risk HPV 261 
types, there was no difference in prevalence between vaccinated and unvaccinated 262 
women. 263 
 264 
319 samples were tested for HPV mRNA (HPV 16, 18, 31, 33 or 45), 172 in Group 1 265 
and 147 in Group 2. Although 14 (25%) samples in the vaccinated group had a 266 
transcriptionally active HPV infection indicated by the mRNA results, there was a 267 
significantly higher proportion of women in the unvaccinated group (63%) with 268 
transcriptionally active HPV infections (p<0.001). Of the vaccinated group, four (7%) 269 
tested positive for HPV 16 mRNA compared to 101 (38%) of the unvaccinated group 270 
(p<0.001).   271 
 272 
Impact of HPV 16 infection on Colposcopic Features and histology 273 
Table S1 in supplementary information shows colposcopic features and histology 274 
results by HPV 16 status  275 
There was no association between presence of HPV 16 DNA or HPV16 mRNA and 276 
any individual colposcopic features.  Despite this, colposcopists were more likely to 277
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record a colposcopic opinion of high grade if participants were HPV 16 DNA positive 278 
(57%;p=0.006) or HPV 16 mRNA positive (59%;p=0.03) than if the woman was HPV16 279 
DNA/mRNA negative (37% and 43% respectively). Women were also more likely to 280 
have a high grade histology result if they were positive for HPV 16 DNA (71%;p<0.001) 281 
or HPV 16 mRNA (77%;p<0.001) than if they tested negative (38% and 43% 282 
respectively). 283 
 284 
Performance of colposcopy 285 
Table 3: Impact of HPV vaccine and HPV 16 on performance of colposcopy  286 
Table 3summarises the performance of colposcopy in vaccinated and unvaccinated 287 
women in terms of sensitivity, specificity, PPV and NPV for the detection of CIN2+.The 288 
HPV vaccination status did not have a statistically significant impact on the 289 
performance of colposcopy. The PPV of colposcopy was 74.0 (95% CI: 63.8-82.1) in 290 
unvaccinated women and 66.7 (95% CI: 35.4-88.7)in vaccinated women although this 291 
difference was not statistically significant (p=0.591).  292 
 293 
HPV 16 presence or absence had a significant impact on the specificity and NPV of 294 
colposcopy for detecting high grade disease (p<0.001).   Colposcopy was found to 295 
have a higher specificity (92.4 (95% CI: 87.1-95.7) compared to 75.0 (95%CI: 62.3-296 
84.6)) and NPV (94.6 (95% CI: 89.7-97.3) compared to 64.9 (95% CI: 52.8-75.4)) in 297 
women who were HPV 16 negative compared to HPV 16 positive.  298 
 299 
Discussion 300 
 301 
Main Findings 302 
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Vaccination in the catch-up cohort is associated with a significant reduction in the 303 
prevalence of HPV 16/18 and CIN2+ in women aged 20-25 years attending 304 
colposcopy in Scotland3. Our results show that colposcopic features were similar in 305 
vaccinated and unvaccinated women and differences were related to the incidence of 306 
cervical disease. Our results indicate that the performance of colposcopy in vaccinated 307 
women has not diminished substantially. However, the PPV for CIN2+ was lower in 308 
vaccinated women (albeit not at a statistically significant level). 309 
 310 
Strengths and Limitations 311 
To our knowledge, this study is the first to investigate the impact of HPV genotypes on 312 
colposcopic features associated with CIN in HPV immunised women. This is possible 313 
as cervical screening in Scotland starts earlier than in many countries, with vaccinated 314 
women entering our national programme in 2010. Scotland achieved high rates of 315 
vaccination in the catch up campaign (65.5%) and has reasonable3 yearly cervical 316 
screening uptake (70.7% overall, 50.9% in 20-24 year olds).15For Group 2 we were 317 
able to assign vaccine status using SCCRS to improve reliability. 318 
 319 
To minimise bias, colposcopists and histopathologists were blinded to HPV results and 320 
staff undertaking the HPV genotyping tests were blinded to vaccine status.  321 
 322 
As the aim of the immunisation is to reduce deaths from cervical cancer, it could be at 323 
least age 30 before this can be confidently measured. The long lead±time between 324 
HPV infection and development of malignancy means that high grade CIN (as used in 325 
our study) is a justifiable surrogate marker for cervical cancer.16 326 
 327 
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Where the cervix appeared normal, biopsies were not taken (as per local protocols) 328 
so these women lacked a ³gold standard diagnosis´ DQGZHUHFODVVLILHGDVµGLVHDVH329 
QHJDWLYH¶IRUDQDO\VLV. A high proportion of women who did not have a biopsy taken 330 
were subsequently found to be HPV 16 negative. This resulted in a high NPV of 331 
colposcopy for detecting high grade disease in HPV 16 negative women, despite there 332 
being no histological confirmation of disease status for them. The NPV of colposcopy 333 
has been previously been recorded as high (up to 96%), so we expect to miss very 334 
few cases of CIN.17,18 335 
 336 
However, as Jeronimo et al.6 suggested that high grade CIN is more likely to be missed 337 
by colposcopy in the absence of HPV 16, it may be that the HPV 16 negative women 338 
with normal colposcopy have disease lacking characteristic colposcopic features. 339 
Follow up of our cohort in the future will address this.  340 
 341 
Interpretation 342 
We believe this is the first study conducted with this primary aim in women who have 343 
received HPV vaccine.6-9Previousstudies reporting on the impact of HPV genotypes 344 
on colposcopy were conducted as ad hoc analyses of larger studies with inconsistent 345 
results. Jeronimo et al. found that HPV 16 was more likely to produce lesions with 346 
colposcopically identifiable features than other HPV types, regardless of histology.6 347 
Louwers et al. reported the presence of HPV 16 significantly improved the sensitivity 348 
of the Dynamic Spectral Imaging colposcopy for CIN and hypothesised that HPV 16 349 
is associated with acetowhitening.7Using data from this same study, Zaal et al. found 350 
that HPV 16 did not impact the performance of standard colposcopy and suggested 351 
that effects were dependent on the underlying grade of disease, rather than HPV16 352 
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per se.8Similarly, van der Marel found that the visual appearance of high-grade HPV16 353 
lesions did not differ from lesions associated with other high-risk HPV types.9 Our 354 
results support this with no significant difference in relation to either vaccine status or 355 
presence of HPV16. Changes in PPV relate to the reduced incidence of high grade 356 
disease in immunised women as PPV is strongly influenced by disease prevalence 357 
and the reduction reflects the reduction in CIN.19With the emerging cohort of women 358 
who received HPV immunisation as part of routine vaccination, rather than catch up, 359 
it is important to clarify the effect of reducing or even eliminating HPV vaccine types 360 
from the screened population as we use colposcopy to identify and treat CIN. 361 
 362 
We did not find any association between HPV 16 and acetowhitening in women 363 
attending colposcopy. Colposcopists were able to identify HPV 16 negative lesions 364 
during colposcopy which were confirmed on biopsy. The women included in our study 365 
were younger (mean age 22.3 years) compared with previous studies (mean age 366 
ranged from 26.2 to 36.7 years).6-9Given that the peak prevalence of HPV infection 367 
occurs in women beforethat of CIN, we anticipate that the impact of HPV genotypes 368 
on colposcopic features may also vary according to age.20 369 
 370 
The vaccinated women in this study received the HPV immunisation as part of the 371 
catch up campaign. The mean age at last dose was 17.3 years. Women were not 372 
asked about sexual activity. It is likely that some women were sexually active and 373 
therefore not HPV naïve prior to vaccination.3,21,22 374 
 375 
Our study suggests that, compared to unvaccinated women, lower proportions of 376 
vaccinated women had high grade cervical cytology. A similar observation has been 377 
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made in Australia.16 This study reported a significant decrease (38%; p=0.003) in high 378 
grade cervical abnormalities in young girls (under 18 years) following the introduction 379 
of the HPV vaccine but no significant decrease in the incidence of low grade cervical 380 
abnormalities in this age category, or in women aged 18-20 years. As the cohort 381 
vaccinated in the school programme at age 12 enters screening, in 2021 in the UK, 382 
we would expect to see a greater impact on PPV with lower disease rates if we do not 383 
review risk stratification of our screening policy. 384 
 385 
 386 
Our results are consistent with those reported in the screened population in Scotland 387 
with a significant reduction in circulating HPV vaccine types and associated 388 
diseaseand provides further evidence of the success of the vaccination 389 
programme.3,20,23 The prevalence of HPV16/18 in vaccinated women attending 390 
colposcopy is similar to that in young women attending cervical screening (11.5% at 391 
colposcopy compared to 11% and 13.6% at screening).3,23 Kavanagh et al. found that 392 
HPV 51 and 56 were the most prevalent HPV genotypes in vaccinated women 393 
attending cervical screening (10.5% and 9.6% respectively).3The prevalence of HPV 394 
51 and 56 was higher in the vaccinated women attending colposcopy compared to the 395 
unvaccinated women (15.7% for each compared to 12.7% and 5.8% respectively in 396 
unvaccinated women) in our study. In contrast to Kavanagh et al, we found that HPV 397 
52 and 59 emerged as the most prevalent HPV genotypes in vaccinated women 398 
attending colposcopy with abnormal cytology (22.9% and 17.1% respectively). 399 
However different HPV assays were used in those studies which may influence HPV 400 
genotype detection.  401 
 402 
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 403 
Conclusion 404 
We found no significant impact of vaccination on colposcopic features in women aged 405 
20-25 with abnormal cervical cytology who had received the HPV 16/18 vaccine as 406 
part of a catch up campaign. Despite the lower prevalence of HPV 16 in vaccinated 407 
women, features considered characteristic of high grade CIN were still detectable. 408 
Cervical screening needs to continue to offer protection from disease from non-409 
vaccine types. However, the reduction in prevalence of CIN has impacted on the PPV 410 
of colposcopy and this has implications for quality assurance of colposcopy in the 411 
cervical screening programme.  412 
 413 
In order to assess the impact of the HPV vaccination on colposcopy performance 414 
further, studies should be conducted when the women who received the vaccine as 415 
part of the school based immunisation programme (in whom the coverage rates were 416 
90%) enter the cervical screening programme.  417 
 418 
Word count 3465 419 
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Figure 1: Flow diagram of recruitment 530 
  531 
Group 1 
208 consented to participate 
Group 2 
175 consented to participate 
10 excluded because no 
sample or insufficient material 
for HPV genotyping 
198 included in final analysis 
12 excluded because: 
11 had no sample or insufficient material 
for HPV genotyping 
1 had missing data proforma  
163 included in final analysis 
172 had HPV 
mRNA  and 
DNA testing 
26 had HPV 
DNA testing 
only 
147 had HPV 
mRNA  and 
DNA testing 
16 had HPV 
DNA testing 
only 
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Figure 2: HPV genotyping results from samples collected at colposcopy 
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Table 1: Participant demographic data by group 
 Group 1 N (column %) 
N=198* 
Group 2 N (column %) 
N=163 
Overall 
N=361 
Vaccinated 
67 (41.1) 
Unvaccinated 
96 (58.9 ) 
Site 
Site 1 95 (48.0)  53 (79.1) 93 (96.9) 241 (66.8) 
Site 2 103 (52.0)  14 (20.9) 3 (3.1) 120 (33.2) 
Age at colposcopy 
20 years 42 (21.2)  17 (25.4) 5 (5.2) 64 (17.7) 
21 years 33 (16.7)  31 (46.3) 5 (5.2) 69 (19.1) 
22 years 29 (14.6)  14 (20.9) 18 (18.8) 61 (16.9) 
23 years 39 (19.7)  3 (4.5) 31 (32.3) 73 (20.2) 
24 years 40 (20.2)  1 (1.5) 17 (17.7) 58 (16.1) 
25 years 15 (7.6)  1 (1.5) 20 (20.8) 36 (10.0) 
Mean Age (years) 22.2 (SD 1.6)  21.2(SD 1.0) 23.2 (SD 1.4) 22.3 (SD 1.6) 
Referral Cytology 
Borderline 46 (23.2)  19 (28.4) 27 (28.1) 92 (25.5) 
Mild dyskaryosis 86 (43.4)  34 (50.7) 28 (29.2) 148 (41.0) 
Moderate dyskaryosis 36 (18.2)  12 (17.9) 28 (29.2) 76 (21.1) 
Severe dyskaryosis 24 (12.1)  2 (3.0) 11 (11.5) 37 (10.2) 
Glandular neoplasia 1 (0.5) - 2 (2.1) 3 (0.8) 
Invasive cancer 1 (0.5) - - 1 (0.3) 
Missing 4 (2) - - 4 (1.1) 
Histology 
Biopsy not taken± 61 (30.8) 27 (40.3) 20 (20.8) 108 (29.9) 
Normal (No CIN) 19 (9.6) 9 (13.4) 10 (10.4) 38 (10.5) 
CIN1 53 (26.8) 18 (26.9) 24 (25.0) 95 (26.3) 
26 
 
CIN2 35 (17.7) 9 (13.4) 23 (24.0) 67 (18.6) 
CIN3 24 (12.1) 3 (4.5) 14 (14.6) 41 (11.4) 
Invasive squamous 1a1 1 (0.5) - 1 (1.0) 2 (0.6) 
CGIN 2 (1.0) - 4 (4.2) 6 (1.7) 
Unsatisfactory 3 (1.5) 1 (1.5) - 4 (1.1) 
Table 1: Comparison of participant demographics between groups."Vaccinated" women refer to women 
who had received 2 or more doses of the HPV vaccination. *Group 1 includes 3 women who reported they 
had received the HPV vaccine.  ±All cases where biopsy was not taken were because colposcopic 
appearances were normal. 
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Table 2: Impact of HPV vaccine on colposcopic features and histology. 
 
Unvaccinated 
n/N (%) 
Vaccinated 
n/N (%) 
chi squared p-
value* (Pearson 
unless indicated) 
Colposcopic Features 
Acetowhite 231/291 (79.4) 54/70 (77.1) 0.623 
Mosaic 129/291 (44.3) 30/70 (42.9) 0.791 
Punctation 111/291 (38.1) 27/70 (38.6) 1.00 
Atypical Vessels 3/291 (1.0) 1/70 (1.4) 0.589 
Iodine Negative** 101/202 (50.0) 33/59 (55.9) 0.029 
Colposcopic Opinion 
High Grade*** 99/290 (34.1) 13/66 (19.7) 0.027 
Histology**** 
CIN2+ 103/286 (36.0) 13/69 (18.8) 0.006 
CIN1+ 179/286 (62.6) 32/69 (46.3) 0.044
 
Table 2 compares the features seen at colposcopy between all participants regardless of disease status 
who were vaccinated against HPV 16 and 18, and women who were not. It also compares the colposcopic 
opinion and histology results between these groups. In patients where biopsies were not taken, they were 
considered to have no disease. 3HDUVRQ¶VWHVWXVHGXQOHVVRWKHUZLVHLQGLFDWHG)LVKHU¶VH[DFWWHVWXVHG. 
**in 100 cases, iodine was not used. This was for a variety of reasons including patient allergy or 
colposcopist preference. ***High grade colposcopic opinion was appearance suggestive of CIN2+. 
****+LVWRORJ\UHVXOWVZHUH³XQVDWLVIDFWRU\´IRUXQYDFFLQDted and 1 vaccinated therefore were excluded 
from histology analysis.  
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Table 3: Impact of HPV 16 on colposcopic features and histology  
 
HPV 16 DNA + 
n/N (%) 
HPV 16 DNA - 
n/N (%) 
chi 
squared 
p-value* 
HPV 16 
mRNA + 
n/N (%) 
HPV 16 
mRNA - 
n/N (%) 
chi 
squared 
p-value* 
Colposcopic Features 
Acetowhite 105/109 (96.3) 104/107 (97.2) 1.00
Ώ 85/87 (97.7) 103/107 (96.3) 0.693
Ώ 
Mosaic 69/109 (63.3) 63/107 (58.9) 0.58 56/87 (64.4) 64/107 (59.8) 0.554 
Punctation 61/107 (57.0) 55/107 (51.4) 0.49 50/86 (58.1) 55/106 (51.9) 0.466 
Atypical Vessels 2/107 (1.9) 1/106 (0.9) 1.00
Ώ 2/85 (2.4) 1/106 (0.9) 0.586
Ώ 
Iodine Negative 
46/109 (42.2) 44/108 (40.7) 
0.41 
37/87 (42.5) 49/108 (45.4) 
0.853 
Colposcopic Opinion 
High Grade 61/108 (56.5) 40/107 (37.4) 0.006 51/86 (59.3) 46/107 (43.0) 0.03 
Histology 
CIN2+ 
77/108 (71.3) 39/103 (37.9) 
<0.001 
67/87 (77.0) 45/104 (43.3) 
<0.001 
Table 3 compares colposcopic features, colposcopic opinion and histology results between participants 
with cervical disease (CIN1+) by HPV 16 DNA status, and by HPV 16 mRNA status. Iodine was not used in 
31 participants who were HPV 16 DNA+, 24 HPV 16 DNA-, 24 mRNA+, 26mRNA-. 3HDUVRQ¶VWHVWXVHGXQOHVV
otherwise indicated. )LVKHU¶VH[DFWWHVWXVHG. 
 
